A child who could not walk began to walk on his own
In the laboratories of the University of Granada, years of patient scientific inquiry have converged into something rare in medicine: a treatment for a disease that had none. Researchers studying primary coenzyme Q deficiency — a genetic disorder that robs children of the cellular energy needed to sustain life — developed a phenolic compound that, when given to a critically ill three-year-old, reversed kidney failure and restored neurological function within six months. The work moves from mouse model to human recovery, tracing the long arc from basic science to a child who can now walk, speak, and grow. In a field where rare diseases often mean abandoned patients, this discovery suggests that rigorous, methodical research can still find its way to the bedside.
- Primary coenzyme Q deficiency strikes young children without warning, dismantling kidney function and brain tissue while offering families almost no therapeutic options and a prognosis measured in months.
- A three-year-old boy arrived at the threshold of this treatment in critical condition — unable to walk, losing weight, suffering brain lesions and steroid-resistant kidney disease that signaled irreversible decline.
- Granada researchers had spent years building a mouse model that faithfully mirrors the human disease, using it to design and validate a phenolic compound intended to restore the body's own coenzyme Q production pathway.
- Within six months of treatment, the child's kidney disease entered complete remission, his neurological damage receded, and he regained independent mobility, language, social engagement, and twenty percent of his body weight.
- The European Medicines Agency has granted orphan drug designation and international patent protection is in place, positioning the therapy for regulatory approval and potential application to other mitochondrial diseases.
For years, researchers at the University of Granada have been studying primary coenzyme Q deficiency, a rare genetic disorder caused by mutations in the COQ2 gene that leaves children unable to produce energy at the cellular level. The disease typically brings kidney failure, brain damage, and a prognosis measured in months. This month, the team published findings in the journal Brain suggesting they may have found a way to stop it.
The path began with a mouse model created at Granada that accurately reproduces the human disease. By tracing how the disorder damages cells and organs in these animals, the team developed a phenolic compound designed to act as a precursor in the body's natural coenzyme Q production. Preclinical results were strong enough to justify moving to a human patient — a three-year-old boy in critical condition, suffering from steroid-resistant kidney disease and encephalopathy with Leigh-like brain lesions, the kind of neurological damage that typically signals no return.
What followed was the outcome researchers rarely allow themselves to expect. Within six months, the child's kidney disease went into complete remission. He regained the ability to walk independently, recovered twenty percent of his body weight, and showed marked improvement in language, social interaction, and cognitive function. Predoctoral researcher Julia Corral Sarasa, who led the study, described watching laboratory work transform a child's life as deeply moving. Senior investigator Luis Carlos López pointed to the case as evidence that a well-designed animal model can illuminate disease mechanisms and guide the rational development of therapies that genuinely work.
The University of Granada has secured orphan drug designation from the European Medicines Agency and filed for international patent protection. The research team is now exploring whether the treatment might benefit patients with other mitochondrial conditions, while the university's research transfer office works toward clinical application and commercialization. For one family, the compound's arrival meant something that had not existed before: a real possibility that their child would survive, and live.
In a laboratory at the University of Granada, researchers have spent years studying a rare and devastating mitochondrial disease that strikes children with little warning and fewer options. Primary coenzyme Q deficiency—a genetic disorder that cripples the body's ability to produce energy at the cellular level—typically leaves its young victims with kidney failure, brain damage, and a prognosis measured in months rather than years. This month, those researchers published findings in the journal Brain that suggest they may have found a way to stop it.
The breakthrough began not with patients, but with mice. Scientists at Granada created a mouse model that faithfully reproduces the human disease, caused by mutations in the COQ2 gene. By studying these animals, the team could trace exactly how the disease damages cells and organs, and test whether a particular phenolic compound—designed to act as a precursor in the body's natural production of coenzyme Q—could reverse the damage. The preclinical results were promising enough to justify moving forward to a human patient.
That patient was a three-year-old boy whose condition had become critical. He suffered from nephrotic syndrome, a kidney disease resistant to steroid treatment, and from encephalopathy with Leigh-like brain lesions—the kind of neurological damage that typically signals irreversible decline. His family had few reasons to hope. When doctors began treating him with the phenolic compound, they were testing a therapy that existed nowhere else in the world.
What happened next was the kind of outcome that researchers dream about but rarely see. Within six months, the boy's kidney disease went into complete remission. His neurological condition improved dramatically. A child who could not walk began to walk on his own. He gained back twenty percent of his body weight. His language skills sharpened. He began to interact socially in ways that had seemed impossible. His cognitive abilities, measured and observed by his family and medical team, showed clear recovery.
Julia Corral Sarasa, the predoctoral researcher who led the study, described the experience of watching laboratory work translate into a living child's recovery as deeply moving. "It has been very moving to see that a treatment we have worked on for years in the laboratory has been able to change the life of a child and his family," she said. Luis Carlos López, the senior investigator overseeing the research, emphasized what the work demonstrates about the path from basic science to the clinic: a carefully designed animal model can reveal disease mechanisms, and those insights can guide the rational development of therapies that actually work in patients.
The implications extend beyond this single case. The University of Granada has secured orphan drug designation from the European Medicines Agency—a regulatory status that recognizes treatments for rare diseases and provides a pathway toward approval and availability. The university has also filed for international patent protection of the therapeutic approach. The research team is now exploring whether the treatment might help patients with other mitochondrial conditions, and whether refinements to the compound itself might improve its effectiveness further.
The work was funded by Spain's State Research Agency and supported by the university's research transfer office, which is now working to move the therapy toward clinical application and eventual commercialization. For a family whose child was dying of a disease with no treatment, the arrival of this compound represented something that had not existed before: a real possibility of survival, and of a life that includes walking, speaking, learning, and growing.
Notable Quotes
It has been very moving to see that a treatment we have worked on for years in the laboratory has been able to change the life of a child and his family.— Julia Corral Sarasa, predoctoral researcher and lead author
This work demonstrates how, starting from an experimental model designed at Granada, you can study disease mechanisms and rationally translate an innovative therapy to the patient, with very promising clinical results.— Luis Carlos López, senior investigator
The Hearth Conversation Another angle on the story
Why does it matter that they started with a mouse model rather than jumping straight to trying the drug in patients?
Because without understanding the disease mechanism first, you're essentially guessing. The mouse model let them see exactly how the genetic mutation breaks the energy-production system in cells, and then test whether their compound actually fixes that broken system. That's the difference between a lucky accident and a rational therapy.
The child improved in six months. Is that fast for this kind of disease?
For a mitochondrial disease with brain damage, it's extraordinary. These conditions typically progress. The fact that he not only stopped declining but actually regained function—walking, talking, gaining weight—suggests the treatment is addressing something fundamental, not just managing symptoms.
What does orphan drug designation actually do for a treatment like this?
It's recognition that this is a drug for a disease so rare that a company wouldn't normally develop it for profit. The designation gives the researchers and the university a clearer regulatory path, faster review, and financial incentives to bring it to patients who need it. Without that, a treatment for a disease affecting a handful of children might never reach those children.
Are they saying this will work for every child with this disease?
No. They've shown it works in one child with a specific genetic mutation. The next step is testing it in more patients to see if the results hold, and whether it helps children with different mutations in the same disease pathway. One case is proof of concept. Multiple cases become evidence.
Why is the timing of the publication significant?
They published during International Mitochondrial Disease Awareness Week. It's a reminder that these diseases exist, that they're being studied, and that progress is possible. For families living with mitochondrial conditions, that timing sends a message: you're not forgotten.